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Cannabis use has been related to an elevated psychosis 
risk and attenuated cognitive functioning. Cannabis-
related cognitive impairments are also observed in popula-
tions along the psychosis dimension. We here investigated 
whether a potential behavioral marker of the psychosis 
dimension (attenuated functional hemispheric asymme-
try) is even further attenuated in individuals using can-
nabis (CU) vs those not using cannabis (nCU). We tested 
29 patients with first-episode psychosis (FEP; 11 CU) and 
90 healthy controls (38 CU) on lateralized lexical deci-
sions assessing left-hemisphere language dominance. In 
patients, psychotic symptoms were assessed by Positive 
& Negative Symptom Scale (PANSS). In controls, self-
reported schizotypy was assessed (The Oxford-Liverpool 
Inventory of Feelings and Experiences: O-LIFE). Results 
indicated that nCU FEP patients had a relative reduced 
hemispheric asymmetry, as did controls with increasing 
cognitive disorganization (CogDis) scores, in particular 
when belonging to the group of nCU controls. Positive, 
disorganized and negative PANSS scores in patients and 
negative and positive schizotypy in controls were unrelated 
to hemispheric asymmetry. These findings suggest that 
cannabis use potentially balances rather than exacerbates 
uncommon hemispheric laterality patterns. Moreover, in 
healthy populations, the potential stabilization of typical 
hemispheric asymmetry in CU might be most relevant to 
individuals with elevated CogDis. We discuss the potential 
beneficial and harmful effects of cannabis use along the 
psychosis dimension together with propositions for future 
studies that should account for the mediating role of addi-
tional substances (eg nicotine), cannabis composition (eg 
cannabidiol content), and individual differences (eg physi-
cal health, or absence of significant polysubstance use). 
Key words: cannabis/drugs/laterality/cognition/schizotypy/ 
psychosis-proneness
Introduction
Psychotic disorders have serious personal1 and societal2 
implications. Early detection may ameliorate or even 
prevent some of these adverse consequences, because it 
relates to more favorable outcomes including milder forms 
and shorter illness duration.3 It is therefore important to 
determine risk factors that enable detection of high-risk 
individuals. Here we consider reduced functional hemi-
spheric asymmetry (hitherto: HA), individuals’ cannabis 
use and symptom profiles in individuals along the psy-
chosis dimension.
HA refers to the fact that certain cognitive func-
tions are differently processed by the cerebral hemi-
spheres, eg language is predominantly processed by 
the left hemisphere.4 In schizophrenia, the establish-
ment of  this HA seems hampered.5 Behavioral studies 
showed reduced left-hemisphere language dominance 
not only in schizophrenia6 but also in healthy schizo-
typal individuals.7,8 The schizotypy concept assumes 
that psychotic symptoms occur along a continuum, 
with severest symptoms being exhibited by patients 
with schizophrenia and mildest symptoms by the 
least affected schizotypal individual from the healthy 
population.9–11 Schizotypy is commonly assessed via 
self-report questionnaires comprising symptom dimen-
sions known from schizophrenia, ie positive, negative 
and disorganized symptoms.10,12,13 Longitudinal stud-
ies showed that high schizotypy scores associate with 
an increased risk for the development of  psychosis.9,14 
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Schizotypy is consequently a valuable risk factor to 
consider.
Another risk factor for the development of psychosis 
is cannabis use.15,16 Acute tetrahydrocannabinol (THC) 
administration, the psychoactive compound in cannabis, 
can induce psychotic symptoms in healthy individuals, 
and exaggerate symptoms in patients.17 Despite this risk 
potential, cannabis is a popular drug along the schizo-
phrenia spectrum, eg in schizophrenia18,19 and schizo-
typy.20,21 Given this link, cannabis may also influence 
performance in cognitive measures such as HA. 
Research investigating the link between cannabis 
and HA is sparse. Inconclusive brain imaging stud-
ies showed (1) increased right-hemisphere activation in 
cannabis users (CU) when compared with noncannabis 
users (nCU) during tasks requiring attentional control,22 
(2) increased right-hemisphere cerebral blood flow with 
acute THC-ingestion,23 and (3) increased hippocampal 
volume in the left over right hemisphere in alcohol and 
marijuana using individuals compared with alcohol 
using individuals.24 Also, some recent studies reported 
comparable dichotic listening performance (assessing 
HA) after THC and placebo consumption.25,26 Better 
known are links between cannabis use and cognitive 
impairments in functions such as memory, executive 
functioning, and attention.27,28 Of interest here, such cog-
nitive impairments are common in schizophrenia29 and 
schizotypy.30,31 Overall, if  both cognitive impairments 
and reduced HA are behavioral markers of  psychosis, 
and cannabis use is a risk factor for psychosis impact-
ing on the brain, one could suggest that both cognitive 
impairments and reduced HA are even more pronounced 
in both psychotic and high schizotypal CU.
Few published studies measured schizotypy, can-
nabis, and cognition simultaneously.32,33 These 
showed that cannabis use was related (1) to exacer-
bated attentional disinhibition and elevated schizo-
typal personality questionnaire subscale scores for 
positive and disorganized schizotypy,32 and (2) to 
enhanced verbal fluency performance in a healthy 
subsample irrespective of  their schizotypy scores.33 
These few studies indicate that cannabis use does not 
associate with both cognitive functioning and ele-
vated schizotypy subscale scores,33 or only with posi-
tive and disorganized subscale scores.32 On the other 
hand, recent studies indicated that cognitive disor-
ganization (CogDis) might be key to both cognitive 
attenuations (including reduced HA)34–38 and also 
associated with drug use,37 whereas positive schizo-
typy seems of  minor clinical relevance.39,40 Negative 
schizotypy seems most heterogeneous when relating 
it to cognitive functions (including HA),32,41–43 and 
substance use.35,36,44
To test for HA as a behavioral marker of  psycho-
sis, and the high-risk potential of  cannabis use, we 
tested whether functional HA for language is most 
attenuated in CU when compared with nCU in 2 
populations along the psychosis dimension, ie first-
episode psychosis (FEP) patients and healthy controls. 
We expected this to be most pronounced with increas-
ing CogDis for the following reasoning, particularly in 
healthy controls: if  CogDis is a vulnerability factor in 
high risk individuals,34,45,46 and cannabis exerts harm-
ful effects in vulnerable populations, cannabis’ harm-
ful effects might be most pronounced in high CogDis 
individuals.
Method
Participants
The fluent English speaking FEP patients and healthy 
right-handed controls had normal or corrected to normal 
vision. Right-handedness was determined according to 
a standardized handedness questionnaire.47 Each right-
hand preference was given a score of  “1,” each either-
hand preference “0.5,” and each left-hand preference 
“0.” We calculated the mean of  the sum of these scores, 
and defined as right-handed those participants who 
scored at least 7.5.35 For patients, both left- and right-
handers were included to maximize sample size. The 29 
FEP patients (12 females) presented at treatment cen-
ters in Nottingham, Bristol, Birmingham, and London. 
They were part of  the ethically approved PsyGrid cohort 
(www.psygrid.org). According to the inclusion and 
exclusion criteria, participants were aged 16–65  years, 
entered secondary care for the first time with psychotic 
symptoms, had sufficient English command and had no 
suspected organic brain disease or history of  learning 
disability.48 The diagnoses were made according to the 
criteria of  experienced psychotic symptoms over the pre-
vious month accompanied by a decrease in functioning. 
The healthy sample was recruited through local adver-
tisements and the University of  Bristol “Experimental 
Hours” scheme for course credits. The latter group per-
formed additional cognitive tasks (to be reported else-
where)49 and a lateralized facial decision task.35 We do 
not report on the latter task, because results were highly 
heterogeneous across numerous studies. In contrast, 
laterality measures obtained when assessing lateral-
ized language functions have been more reliable.4 These 
individuals were also asked about their highest finished 
education. The University of  Bristol ethics committee 
approved this study. All participants provided written 
informed consent prior participation.
Psychotic Symptoms and Premorbid IQ in Patients
Psychotic symptoms in FEP patients were assessed with 
the Positive & Negative Symptom Scale (PANSS).50 We 
here considered the positive and negative symptom scales, 
as well as factor-analytic solutions for the CogDis scale 
comprising poor attention, difficulties in abstract thinking, 
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and conceptual disorganization.51 Trained clinical inter-
viewers at each centre enquired about psychotic symptoms 
over the previous week. Interviewing skills and inter-rater 
reliability (ICC) were regularly checked. The ICC was 0.95 
(95% CI 0.67–1.0) for positive symptoms and 0.92 (95% 
CI 0.51–1.0) for negative symptoms. Patients also com-
pleted the National Adult Reading Test (NART), assess-
ing premorbid reading ability by measuring the number of 
irregular words correctly pronounced52 (the more correct 
pronunciations, the higher the verbal IQ).
Schizotypy and Educational Level in Healthy 
Participants
The 159 true-false item Oxford-Liverpool Inventory 
of Feelings and Experiences10,53 assesses Unusual 
Experiences (UnEx, positive schizotypy, 30 items such 
as “Are your thoughts sometimes so strong that you can 
almost hear them?”), Introvertive Anhedonia (IntAn, 
negative schizotypy, 27 items such as “Do you prefer 
watching television to going out with people?”), and 
CogDis (24 items such as “Are you easily confused if  too 
much happens at the same time?”). The higher the sum 
score, the higher the schizotypy score. Normative values 
can be found in Mason et al.10,53 Participants were also 
asked about their highest finished education (ie second-
ary school, college, university, or other).
Drug Use and Medication
Within PsyGrid, patients were only asked which drugs 
they mainly use and with which frequency, ie occasional 
(less than weekly), regular (at least weekly), or frequent 
[(almost) everyday] use. The same criteria for frequency 
were also applied to healthy controls. In both groups, 
other drugs were only used occasionally. At study entry, 
2 patients were medically treated (once Mitrazepine, once 
Benzodiazepine), 16 patients had incomplete medica-
tion records, and 11 were medication-free. The duration 
between presenting at the treatment centers and actual 
study entry ranged between 1 and 3 months.
In the healthy sample, we excluded volunteers who 
reported excessive alcohol use (>50/>35 units of alcohol 
per week for men/women, respectively), and/or alcohol 
use within 12 h prior testing. In the study information, 
we informed participants that we would perform urine 
drug screening. At study entry, we asked about illegal 
substance use within the past 3  months. To encourage 
honest responding, we kept volunteers unaware that the 
urine drug test would only detect cannabis metabolites 
until about 2 weeks after its consumption. Participants 
were excluded if  they indicated illicit drug use (apart from 
cannabis) in the past 3  months (>twice) and/or within 
the last 2 weeks. We kept participants with a negative 
THC-derivate urine test if  they had reported occasional 
use within the past 30 days, and/or indicated regular or 
frequent use in the past 30 days, but not within the past 
2 weeks. Participants were excluded, if  they indicated 
regular or frequent cannabis use within the past 2 weeks 
despite a negative drug test. We also excluded healthy 
nCU if  they did not report nicotine and cannabis use in 
the past 30 days but showed a positive drug test.
Lateralized Lexical Decision Task
Our Lateralized Lexical Decision Task (LDT) paradigm 
is based on common procedures used for lateralized half-
field studies54 and has been used before.8,35 The stimuli 
consisted of  4- and 5-letter words matched for neighbor-
hood and CELEX frequency.55 A fixation cross was dis-
played in the centre of  the screen for 1000 ms, followed 
by the presentation of  2 strings of  letters on either side 
of  the screen for 150 ms. After this, a blank screen was 
presented. For a maximum of  4000 ms, participants had 
to indicate whether they saw a word on the left (press-
ing the left shift key with their left index finger) or right 
(pressing the right shift key with their right index fin-
ger), or saw no meaningful English word on either side 
of  the screen (pressing the space bar with both thumbs, 
see35 for further details). Each word was matched with a 
nonword of  the same length. The remaining non-words 
were matched to result in an additional set of  nonword 
pairs. There were 72 trials with three 24-trial conditions: 
(1) word left/nonword right, (2) nonword left/word 
right, and (3) nonword/nonword. The word pairs were 
displayed in black (33 point Courier New Bold font) on 
a grey background on the computer screen. Each let-
ter string was presented with their center 25 mm from 
central fixation (visual eccentricity: 2.5 degrees of  visual 
angle per half-field). Prior to the experimental task, each 
participant undertook a practice block consisting of  10 
trials with words and nonwords not used in the experi-
mental trial. The order of  the stimuli was randomized 
between participants. We assessed the number of  correct 
lexical decisions and the mean reaction times for correct 
lexical decisions for the left visual field (LVF) and right 
visual field (RVF) separately.
Data Analysis
We excluded individual response latencies faster than 2 × 
SD from the individual means in the LDT.35,36 Additional 
exclusion criteria included age and random responding. 
We excluded participants older than 40 years or missing 
age information (1 CU control, 2 CU patients, 1 nCU 
patient). We excluded 1 nCU control and 1 nCU patient 
performing at or below chance level for both LVF and 
RVF performance. Missing PANSS values (13.8% of 
all cases; Little’s Missing Completely at Random test: 
Χ2 = 11.57, df = 14, P = .64) were estimated according to 
EM-methods of the SPSS missing value analysis.56
Kolmogorov-Smirnov tests revealed normal distri-
bution for the LDT LVF %, the The Oxford-Liverpool 
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Inventory of Feelings and Experiences (O-LIFE) 
CogDis scale, and for the PANSS positive and negative 
symptom scores. All other variables (O-LIFE UnEx, 
O-LIFE IntAn, PANSS CogDis, age, handedness, and 
other laterality variables) were not normally distributed. 
Consequently, we ran all correlational analyses using 
Spearman’s rho. F-tests are fairly robust to violations of 
normality.57 Thus, we calculated 2 × 2 × 2 mixed sample 
ANCOVAs controlling for age and handedness, with 
visual field (LVF, RVF) as the related samples factor, and 
mental health group (patients, healthy controls) and can-
nabis use (yes, no) as the independent samples factors 
on mean reaction times for correct lexical decisions. The 
same ANCOVA was also calculated for percent correct 
lexical decisions. Effect sizes are reported throughout. All 
P values were 2-tailed, the α-level was set at .05.
Results
Participants
Of the 11 CU FEP, 2 were occasional CU, 3 used cannabis 
on a regular basis and 6 on a frequent basis. Of the 38 CU 
controls, 3 were occasional users, 16 were regular users 
and 19 were frequent users (the latter 2 groups yielded 
positive urine tests). Pearson-Chi square analyses revealed 
that the frequency of occasional, regular and frequent 
users did not differ between patients and controls [Χ2(3, 
N = 119) = 1.49, P = .68]. The NART scores were compa-
rable for CU and nCU patients (t(27) = 0.45, P = .66). CU 
controls did not differ from nCU controls on measures of 
highest finished education [Χ2(2, N = 90) = 1.63, P = .44].
Univariate analysis of variances with cannabis use and 
nonuse (CU, nCU) and mental health group (patients, 
controls) as between-subjects factors on age and handed-
ness, separately, revealed that age did not differ between 
CU and nCU [F(1,115) = 0.98; P = .32, partial η2 = 0.01], 
nor did handedness [F(1,115)  =  0.99; P  =  .32, partial 
η2 = 0.01]. However, patients were significantly older than 
controls [F(1,115) = 10.93; P < .01, partial η2 = 0.09], and 
were less right-handed than controls [F(1,115) = 36.27; P 
< .001, partial η2 = 0.24, table 1]. There was no significant 
interaction between cannabis use and mental health nei-
ther for age [F(1,115) = 0.44; P = .51, partial η2 < 0.01] 
nor handedness [F(1,115) = .18; P = .68, partial η2 < .01, 
table 1].
Spearman’s rho correlations revealed that age and 
handedness correlated with at least one laterality measure 
(table 2). Therefore, these variables were controlled for in 
subsequent analyses.
The Relationship Between Cannabis Use and Mental 
Health on HA
The mixed-samples ANCOVA on percent correct 
responses showed a significant drug use * mental health 
* visual field interaction [F(1,113) = 4.13, P = .04, partial 
η2 = 0.04]. The same mixed-samples ANCOVA split by 
cannabis use revealed a significant mental health * visual 
field interaction in nCU [F(1,66) = 5.45, P = .02, partial 
η2 = 0.08], but not in CU [F(1,45) = 1.56, P = .22, partial 
η2 = 0.03]. Paired-samples t-tests split by mental health 
in nCU revealed significantly better RVF than LVF per-
formance in controls (t(51) = −5.77, P < .001, Cohen’s 
dz = −0.80), but not in patients (t(17) = −0.85, P = .41, 
Cohen’s dz = −0.20; table 3).
All other comparisons were nonsignificant (all P > 
.05). The same ANCOVA on reaction times showed 
that patients were significantly slower than controls 
[F(1,113) = 4.89, P =  .03, partial η2 = 0.04, table3]. All 
other comparisons were nonsignificant (all P > .05).
Psychotic (-Like) Symptoms and HA
The t-tests on PANSS scores separately showed that 
CU patients had more positive symptoms than nCU 
patients (table 4). Negative and CogDis symptoms were 
Table 1. Age and Handedness for FEP Patients and Controls
Controls (N = 90) Patients (N = 29)
Cannabis users (N = 38) Nonusers (N=52) Cannabis users (N = 11) Nonusers (N = 18)
Mean SD Mean SD Mean SD Mean SD
Age (years) 21.97 3.97 21.67 3.49 25.64 6.55 24.11 4.90
Handedness 11.51 0.71 11.24 0.84 8.86 4.70 8.19 3.92
Table 2. Spearman’s Rho Correlations for the Association 
Between LDT Performance Measures, Age, and Handedness in 
the Entire Sample (N = 119)
Age Handedness
LVFa %b −0.05 −0.20*
RVFc % −0.00 −0.05
LVF RT 0.12 −0.16**
RVF RT 0.23* −0.16**
Note: LDT, Lexical Decision Task; LVF, left visual field; RVF, 
right visual field; RT, reaction time. 
aLeft visual field; bPercent correct; cRight visual field.
*Significant at P ≤ .05; **significant at P ≤ .10.
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comparable between groups (table 4). Partial Spearman’s 
rho correlations controlling for age and handedness indi-
cated no association between PANSS subscale scores and 
the laterality measures (all P > .09; table 5). In controls, 
t-tests comparing the O-LIFE subscale scores between 
CU and nCU were all nonsignificant (table 4).
In controls, partial Spearman’s rho correlations con-
trolling for age and handedness indicated that increas-
ing CogDis scores correlated with an enhanced LVF 
accuracy and a marginally decreased LVF RT (table 5). 
When testing these relationships for CU and nCU con-
trols separately, increasing CogDis scores correlated with 
an enhanced LVF accuracy in nCU only (table  5). In 
patients, the same analysis revealed no significant corre-
lations (see also table 5).
Discussion
We investigated the relationship between cannabis use, 
psychotic (-like) symptoms and HA, a purportedly bio-
logical marker along the psychosis spectrum. Using a 
lateralized LDT, we investigated firstly if  CU relates 
to a more pronounced attenuation in HA than nCU in 
FEP and controls, respectively, and secondly if  any such 
relationship in controls would be particularly true for 
CogDis. Results showed that nCU FEP patients had a 
reduced HA, as did controls with increasing CogDis, in 
particular when belonging to the group of nCU. Positive, 
negative and CogDis PANSS scores in patients and 
IntAn and UnEx scores in controls were unrelated to 
functional HA.
Reduced HA, in particular for language, might be a 
behavioral marker for schizophrenia.58 Behavioral stud-
ies strengthened this notion reporting reduced left-hemi-
sphere dominance for language in both schizophrenia6 
and healthy schizotypy.7,8 Supporting the influence of 
drug use,35,36 we only observed this laterality reduction in 
nCU FEP and controls with increasing CogDis, in par-
ticular when belonging to the group of nCU.
The first finding is initially surprising, we expected can-
nabis (mainly smoked with nicotine) to reduce left hemi-
sphere language dominance for several reasons. Firstly, 
epidemiological studies show enhanced cannabis use 
along the schizophrenia spectrum (eg schizophrenia,18,19 
schizotypy).20,21 Secondly, acute THC administration 
can induce psychotic symptoms in healthy participants, 
and exacerbate symptoms in patients.17 Thirdly, canna-
bis use in patients associates with an unfavorable illness 
Table 3. Means and SD for LDT Performance for the Total Sample and the Study Groups Separately
LVFa %b RVFc % LVF RT RVF RT
All N = 119 Mean 55.60 72.58 827.09 807.25
SD 22.97 15.04 210.49 228.07
Controls CU (N = 38) Mean 54.28 69.30 801.60 797.66
SD 22.29 14.58 156.77 177.65
nCU (N = 52) Mean 55.29 76.20 761.59 730.96
SD 23.77 13.13 137.90 130.87
Patients CU (N = 11) Mean 51.14 75.38 1021.01 990.28
SD 25.01 16.08 205.17 383.94
nCU (N = 18) Mean 62.04 67.36 951.59 936.06
SD 21.34 18.43 341.91 311.47
Note: CU, using cannabis; nCU, not using cannabis; RT, reaction time.
aLeft visual field; b% correct; cRight visual field
Table 4. PANSS and O-LIFE Scores and Their Distribution, Split by Mental Health Group and Cannabis Use
Patients Controls
CU (N = 11) nCU (N = 18) CU (N = 38) nCU (N = 52)
Mean (SD) Mean (SD) Mean (SD) Mean t P Cohen’s d
PANSS Positive 18.28 (6.9) 13.06 (4.4) n/a n/a 2.25 .04 0.99
CogDisa 6.10 (3.36) 4.45 (1.86) n/a n/a 1.72 .10 0.68
Negative 14.68 (5.69) 13.5 (4.53) n/a n/a 0.62 .54 0.25
O-LIFE UnExb n/a n/a 7.39 (5.82) 5.63 (3.91) 1.62 .11 0.37
CogDis n/a n/a 10.74 (5.71) 11.04 (5.1) −0.26 .79 −0.06
IntAnc n/a n/a 3.95 (3.21) 4.85 (3.72) −1.2 .23 −0.26
Note: CU, using cannabis; nCU, not using cannabis; PANSS, Positive & Negative Symptom Scale.
aCognitive disorganization, bUnusual experiences, cIntrovertive anhedonia.
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outcome, ie earlier onset, more frequent hospitaliza-
tion and relapse.59 Finally, cannabis use can be harmful 
for cognition in FEP21 and healthy controls.27,28 Yet, we 
observed a reduced functional HA in nCU (instead of 
CU) FEP and in controls with increasing CogDis, in par-
ticular in nCU. Functional HA was comparable for CU 
FEP, nCU controls and CU controls, with no significant 
influence of CogDis in the latter sample. Thus, cannabis 
use was associated with the commonly observed [and not 
“psychotic-(like)”] laterality pattern.
Studies testing the influence of cannabis use on func-
tional HA are scarce. Some results indicate that THC 
when compared with placebo is associated with greater 
RH activation.60 Others found comparable dichotic lis-
tening performance after THC and placebo consump-
tion.25,26 Given the scarcity of HA studies, we considered 
links between cannabis use and cognition more widely. 
These studies revealed various cognitive impairments 
in CU when compared with nCU including memory, 
attention and executive functions.27,28 Such cognitive 
impairments seem common in schizophrenia29 and also 
schizotypy30,31 indicating that cannabis use along the 
psychosis dimension might link to even worse cognitive 
impairments. Yet, cognitive functions are usually superior 
in CU when compared with nCU patients.61,62 Cannabis 
use may be related to enhanced prefrontal neurotransmis-
sion and consequently superior cognitive performance in 
patients.63 Finally, cannabis use enhanced verbal fluency 
performance in healthy participants low on trait creativ-
ity.33 Thus, CU might actually restore cognitive function-
ing (including common patterns of HA as observed here).
To conjecture the kind of restorative processes, the 
neuronal underpinnings of cannabis use seem widespread 
anatomically and functionally.64 What seems, however, 
common is that neuronal activity and connectivity has 
been found to be altered in CU when compared with 
nCU, being potentially indicative of compensatory func-
tions.64,65 Given that left-hemisphere dysfunctions have 
long been linked to psychotic conditions,8,58 cannabis 
might facilitate the activation and strengthening of such 
relatively impaired neuronal networks, and as such help to 
compensate for neuronal deficits, ie left-hemisphere defi-
cits in the current case. We do not know whether any such 
compensation might become established over time65,66 
and/or exerts its action in the short-term.67 In particular 
for visual lexical decisions, potential mechanisms restor-
ing asymmetry might not necessarily imply better cogni-
tive functioning.68 Moreover, we do not know whether 
observed changes in chronic CU are directly explained by 
cannabis use or point to vulnerability markers associated 
with the long-term use of cannabis.66
Alternatively or complementarily, premorbid IQ and 
years of education did not differ between CU and nCU 
patients and controls, respectively. Thus, intellectual abil-
ities are unlikely to explain our findings.69 We propose 
that our cannabis effects result from (1) beneficial prop-
erties of certain cannabinoid components and (2) indi-
vidual differences such as enhanced psychopathological 
vulnerability yielding different sensitivities to cannabis 
use. Firstly, neuroprotective (antioxidant, anti-inflam-
matory) properties of some cannabis components have 
been identified.70,71 Cannabidiol is such a neuroprotective 
Table 5. Partial Spearmans’ Rho Correlations Controlling for Age and Handedness Investigating the Association Between Psychotic 
(-Like) Symptoms and LDT Performance Measures, Split by Mental Health Status and Drug Use
LVFd %e RVFf % LVF RT RVF RT
Controls (N = 90) UnExa 0.02 0.07 0.01 0.03
CogDis b 0.25* 0.03 −0.19** −0.08
IntAn c 0.05 0.05 −0.07 −0.05
CU (N = 38) UnEx −0.14 −0.04 0.07 0.11
CogDis 0.19 0.02 −0.11 0.08
IntAn 0.22 0.08 0.06 0.1
nCU (N = 52) UnEx 0.17 0.13 0.01 0.03
CogDis 0.29*** 0.06 −0.15 −0.1
IntAn −0.05 0.01 −0.14 −0.12
Patients (N = 29) Positive −0.15 0.12 0.10 0.07
CogDis 0.26 0.23 −0.11 −0.01
Negative 0.14 0.28 0.05 −0.08
CU (N = 11) Positive −0.17 0.05 −0.09 −0.05
CogDis 0.17 0.07 0.26 0.34
Negative 0.17 −0.09 0.02 0.24
nCU (N = 18) Positive 0.23 −0.20 −0.13 −0.04
CogDis 0.43 0.20 −0.29 −0.23
Negative 0.14 0.38 −0.05 −0.28
Note: CU, using cannabis; nCU, not using cannabis; RT, reaction time.
*P = .02; **P = .07; ***P = .04
a Unusual experiences, b cognitive disorganization, c introvertive anhedonia,d left visual field, epercent correct, f right visual field. 
S461
Laterality, Psychotic (-Like) Thinking, and Cannabis
component.72 Fewer psychotic experiences in the general 
population73,74 and putative benefits for cognitive func-
tioning75 have been associated with cannabis high in can-
nabidiol. This substance may activate neuroprotective 
effects outlasting acute intoxication periods and coun-
teracting negative consequences of psychopathological 
changes.
Secondly, research exploring which patients may ben-
efit from CU regarding cognitive functioning has been 
rather scarce. Other outcome measures, however, may hint 
at which individuals may benefit from CU. For instance, 
some patient subgroups seem to experience symptom 
alleviation with synthetic THC-administration,76 ie 
patients with no significant polysubstance use, good 
physical health, and severe, longstanding illness refrac-
tory to standard treatment. The sample size in this report 
was, however, small (4 participants). Other outcome vari-
ables such as psychopathological symptoms in patients 
seem unrelated to CU after controlling for variables such 
as additional substance use, or baseline illness severity.77
In schizotypy, cognitive impairments are commonly 
linked to schizotypal subdimensions, and when consid-
ering HA and drug use, reduced HA seems particularly 
linked with CogDis (as measured by the O-LIFE).10,35,36 
We conjecture that CogDis is the schizotypal subdimen-
sion related to psychopathological risk. Independent 
patient studies reported on increased right hemisphere 
functioning with enhanced CogDis,78 or cognitive attenu-
ations.46 Moreover, CogDis has been shown to be sensitive 
to relatively well-established endophenotypes of psycho-
sis in healthy schizotypal populations.34–38 Importantly, 
the basic symptom criterion “cognitive disturbances” 
together with ultra-high risk symptoms are crucial for 
predicting psychosis.45 CogDis also seems to mediate the 
relationship between positive and negative symptoms.79 
Thus, our CogDis findings are also supporting indepen-
dent notions that positive schizotypy is of minor rel-
evance to psychopathology,39,40 and negative schizotypy 
relates inconsistently with cognitive and behavioral mea-
sures (including HA).35–37,80
Limitations
The current multicenter study protocol provided only 
limited drug use information in patients. More infor-
mation would be important, because polydrug use has 
been associated with better cognitive performance in 
patients.63 Also, CU patients frequently consume oth-
ers substances, mainly nicotine.81 Nicotine use has been 
linked to increased transition rates in high-risk samples.82 
An increased nicotine exposure via cannabis smoking 
might actually associate with reduced HA in patients, 
and not cannabis alone. Nicotine dependence in a student 
population correlated with enhanced right hemisphere 
language functions35 and right ear advantage in a dichotic 
listening task (men only).83 Moreover, nicotine exposure 
increased RH thalamic blood flow in overnight abstinent 
smokers.84,85
Additionally, the absence of a relationship between 
CogDis scores and HA in patients may be due to a differ-
ence in scale composition. The O-LIFE CogDis-scale also 
comprises social anxiety items,10 whereas this is not the 
case for most factor-analytic solutions of the PANSS.51 
We therefore suggest that future studies use the same, or 
develop a comparable instrument to measure the con-
struct of CogDis in healthy and mentally ill populations.
Conclusions
We investigated the relationship between psychotic (-like) 
symptoms, cannabis use and HA, a purportedly biologi-
cal marker along the psychosis spectrum. More specifi-
cally, we set out to investigate if  (1) CU relates to a less 
pathological HA profile in FEP and (2) if  in healthy con-
trols CogDis would relate to a more pathological laterality 
profile, particularly pronounced in CU when compared 
with nCU. We found that a psychotic-like attenuation of 
the typical LH language dominance was found in both 
nCU FEP and healthy controls with increasing CogDis, 
in particular when belonging to the group of nCU. These 
findings suggest that cannabis use may stabilize laterality 
patterns in vulnerable populations, ie patients with FEP 
and healthy individuals scoring high on CogDis. Future 
studies should address the additional role of nicotine, 
cannabidiol, and other substances on functional HA and 
pathological risk, as well as the role of individual differ-
ences in cannabis use and their effect on mental health.
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